Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed as a novel class of anti-hyperglycaemic drugs, have been shown to significantly improve metabolic indicators and protect the kidneys and heart of patients with or without type 2 diabetes mellitus. The possible mechanisms mediati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yue-Ming, Feng, Song-Tao, Wen, Yi, Tang, Tao-Tao, Wang, Bin, Liu, Bi-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396537/
https://www.ncbi.nlm.nih.gov/pubmed/35973390
http://dx.doi.org/10.1016/j.ebiom.2022.104215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396537/
https://www.ncbi.nlm.nih.gov/pubmed/35973390
http://dx.doi.org/10.1016/j.ebiom.2022.104215

Ejemplares similares